Paion AG (PAIOF) Research

Paion AG is a specialized biopharmaceutical company that operates globally, focusing on the development and commercialization of medications intended for hospital settings, specifically for sedation, anesthesia, and critical care management. Its primary product in development is Remimazolam, an ultra-short-acting intravenous benzodiazepine-class drug serving as both a sedative and an anesthetic, which is currently undergoing clinical trials for applications in procedural sedation, general anesthesia, and intensive care unit sedation. The company's pipeline further includes Angiotensin II, a vasoconstrictor designed for adults experiencing refractory low blood pressure due to septic or other forms of distributive shock, and Eravacycline, a novel fluorocycline antibiotic aimed at treating complicated intra-abdominal infections in adults. Paion AG maintains strategic partnerships and licensing arrangements with several entities, including Cosmo Pharmaceuticals, Wuhan Humanwell Innovative Drug Research and Development Center Limited Company, Hana Pharm, Yichang Humanwell, and Mundipharma. The company was founded in the year 2000 and has its headquarters in Aachen, Germany.

Open Paion AG (PAIOF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.